CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 8.7: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
4.80BCNY712.22M · vs all stocks (USD)
Revenue (TTM)
225.16MCNY33.44M · vs all stocks (USD)
Profit Margin
-95.82%vs Biotechnology peers
Beta
0.5730xvs all stocks
52-Week Change
45.58%vs all stocks
Market Capitalization
4.80BCNY712.22M · vs all stocks (USD)
Enterprise Value
5.05BCNY750.01M · vs all stocks (USD)
Price to Sales (TTM)
22.58xvs Biotechnology peers
Price to Book (MRQ)
5.47xvs Biotechnology peers
Enterprise to Revenue
22.43xvs Biotechnology peers
Enterprise to EBITDA
-91.72xvs Biotechnology peers
Gross Margin
59.50%vs Biotechnology peers
Profit Margin
-95.82%vs Biotechnology peers
Operating Margin
14.62%vs Biotechnology peers
Return on Assets (TTM)
-4.85%vs Biotechnology peers
Return on Equity (TTM)
-20.89%vs Biotechnology peers
Revenue (TTM)
225.16MCNY33.44M · vs all stocks (USD)
Revenue per Share (TTM)
1.55CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-0.20%vs Biotechnology peers
Gross Profit (TTM)
45.82MCNY6.80M · vs all stocks (USD)
EBITDA (TTM)
-55.06MCNY-8.18M · vs all stocks (USD)
Net Income (TTM)
-215.74MCNY-32.04M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-454.50%vs Biotechnology peers
Operating Cash Flow (TTM)
52.68MCNY7.82M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-24.73MCNY-3.67M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
13.29MCNYFY2025 · Dec 31, 2025Revenue
225.27MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
155.29MCNYFY2025 · Dec 31, 2025Gross Profit
69.98MCNYFY2025 · Dec 31, 2025Operating Income
-85.60MCNY-12.71M · vs all stocks (USD)
Pre-tax Income
-208.48MCNYFY2025 · Dec 31, 2025Income Tax Expense
21.26MCNYFY2025 · Dec 31, 2025Net Income
-229.73MCNYFY2025 · Dec 31, 2025EBIT
-202.20MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-28.32MCNYFY2025 · Dec 31, 2025Research & Development
9.37MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
79.32MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.60MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.36MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
6.27MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.57CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.57CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
144.80MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
144.80MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-229.73MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.39MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
21.16MCNYFY2025 · Dec 31, 2025Free Cash Flow
-45.93MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
127.19MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-229.73MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.38MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
165.64MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
77.87MCNYFY2025 · Dec 31, 2025Capital Expenditures
-67.08MCNYFY2025 · Dec 31, 2025Net Acquisitions
44.63MCNYFY2025 · Dec 31, 2025Other Investing Activity
-20.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-42.46MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
65.30MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-187.82MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-28.42MCNYFY2025 · Dec 31, 2025Other Financing Charges
-111.57KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-151.06MCNYFY2025 · Dec 31, 2025Shares Outstanding
144.79MSharesUpdated Aug 20, 2026Float Shares
37.73MSharesUpdated Aug 20, 2026% Held by Insiders
73.04%vs all stocks
% Held by Institutions
0.30%vs all stocks
Total Cash (MRQ)
191.90MCNY28.50M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.35CNYUpdated Aug 20, 2026Total Debt (MRQ)
239.58MCNY35.58M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2589xvs Biotechnology peers
Current Ratio (MRQ)
1.95xvs Biotechnology peers
Book Value per Share (MRQ)
6.42CNYUpdated Aug 20, 2026Total Assets
1.25BCNY185.83M · vs all stocks (USD)
Total Current Assets
383.25MCNYFY2025 · Dec 31, 2025Total Liabilities
327.50MCNYFY2025 · Dec 31, 2025Total Non-current Assets
867.98MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
142.08MCNYFY2025 · Dec 31, 2025Total Current Liabilities
185.42MCNYFY2025 · Dec 31, 2025Cash
137.10MCNYFY2025 · Dec 31, 2025Cash Equivalents
316.96KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
137.42MCNYFY2025 · Dec 31, 2025Other Short-term Investments
10.02MCNYFY2025 · Dec 31, 2025Accounts Receivable
109.36MCNYFY2025 · Dec 31, 2025Inventory
60.87MCNYFY2025 · Dec 31, 2025Accounts Payable
47.01MCNYFY2025 · Dec 31, 2025Short-term Debt
73.27MCNYFY2025 · Dec 31, 2025Other Current Liabilities
7.48MCNYFY2025 · Dec 31, 2025Long-term Debt
91.67MCNYFY2025 · Dec 31, 2025Common Stock (Book)
144.79MCNYFY2025 · Dec 31, 2025Retained Earnings
69.68MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
923.73MCNY137.19M · vs all stocks (USD)
Treasury Stock
50.00MCNYFY2025 · Dec 31, 202552-Week Low
19.95CNYUpdated Aug 20, 202652-Week High
40.22CNYUpdated Aug 20, 202652-Week Change
45.58%vs all stocks
Beta
0.5730xvs all stocks
50-Day MA
31.80CNYUpdated Aug 20, 2026200-Day MA
29.13CNYUpdated Aug 20, 2026Avg 10-Day Volume
4.94MSharesUpdated Aug 20, 2026Avg 30-Day Volume
5.11MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-1.49CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 22.58Revenue Growth YoY: -0.00
High gross margins eroded by operating costsNotable
Gross Margin: 0.59Profit Margin: -0.96
Financial Health
Altman Z-Score 8.7: safe zoneNotable
Altman Z-Score: 8.70
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Lifotronic Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ceribell, Inc.
Tier 1ProductionApproval-Gated PipelineRule
XOMA Corporation
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
Beijing Beilu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hvsen Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shattuck Labs Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Teyi Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aura Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Omeros Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk